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ABSTRACT 
Background: Only few studies in selected cohorts have examined whether the CHA2DS2-
VASc score can predict the risk of atrial fibrillation and thromboembolic events in patients 
without atrial fibrillation. 
 
Materials and methods: Patients with coronary angiography performed between 2004-2012 
were grouped according to CHA2DS2-VASc score. We excluded patients with atrial 
fibrillation, anticoagulant therapy, and follow-up <30 days. The endpoints were atrial 
fibrillation and a composite of ischemic stroke, transient ischemic attack, and systemic 
embolism. Event rates per 100 person-years were estimated for each CHA2DS2-VASc score 
(0, 1, 2, 3, 4, and >4). Incidence rate ratios were calculated using low-risk patients 
(CHA2DS2-VASc score 0 in males or 1 in females) as reference. 
 
Results: In total, 78,233 patients were included with group sizes varying between 8,299 
(CHA2DS2-VASc >4) and 19,882 (CHA2DS2-VASc 2). An increasing CHA2DS2-VASc score 
was significantly associated with a future diagnosis of atrial fibrillation (p for trend <0.0001) 
and an incremental risk of ischemic stroke, transient ischemic attack, systemic embolism (p 
for trend <0.0001), and all-cause death (p for trend <0.0001). Patients with a CHA2DS2-
VASc score of 3 had a rate of ischemic stroke/transient ischemic attack/systemic embolism of 
1.30 per 100 person-years.  
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Conclusions: Among patients undergoing coronary angiography, the CHA2DS2-VASc score 
predicted a future diagnosis of atrial fibrillation and the composite risk of ischemic stroke, 
transient ischemic attack, or systemic embolism in patients without atrial fibrillation. A 
CHA2DS2-VASc score of 3 was associated with a risk that would justify prophylactic oral 
anticoagulation treatment in a patient with atrial fibrillation. 
 
Keywords: Prevention, stroke, coronary artery disease, coronary angiography, 
thromboembolism, CHA2DS2-VASc  
 
INTRODUCTION 
Atrial fibrillation (AF) is well-recognized as a cause of ischemic stroke due to 
embolization of thrombus, most often formed in the left atrial appendage.
1
 Among AF-
patients, the risk of ischemic events can be assessed by the CHA2DS2-VASc score 
(congestive heart failure, hypertension, age, diabetes mellitus, previous stroke/transient 
ischemic attack (TIA), vascular disease (previous myocardial infarction (MI), or peripheral 
artery disease (PAD)/aortic plaque), and female sex),
2,3
 which is used to guide the initiation 
of oral anticoagulants (OAC). Currently, a single non-gender stroke risk factor using the 
CHA2DS2-VASc score (CHA2DS2-VASc score of 1 in males and 2 in females), 
corresponding to an annual risk of ischemic stroke/TIA/systemic embolism >1%, is used to 
indicate OAC therapy according to European guidelines.
2,4–6
 Treatment with OAC, i.e. 
vitamin K antagonists or non-vitamin K antagonist OAC (NOAC), reduces the risk of 
thromboembolism by two-thirds in AF-patients.
7–9
 
However, only 20-30% of patients with thromboembolism are diagnosed with 
AF prior, or in relation, to their ischemic stroke.
10
 Identification of non-AF patients at high 
risk of developing AF or ischemic stroke/TIA/systemic embolism may enable preventive 
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strategies. We examined whether the CHA2DS2-VASc score can be used to identify non-AF 
patients at high risk of developing AF or ischemic stroke and thromboembolism.   
 
MATERIALS AND METHODS 
 We conducted a registry-based cohort study of Danish residents undergoing 
coronary angiography (CAG) in Western Denmark between 2004-2012. All CAGs are 
registered in the Western Denmark Heart Registry (WDHR).
11
 In case of multiple 
examinations, the first CAG was used as index CAG.  
Setting: Denmark provides a tax-payer funded national health care system, 
ensuring free access to health care for all Danish residents, who are assigned a unique 10-
digit personal identifier upon birth or after immigration. The identifier is used throughout 
every regional and national registry, ensuring accurate cross-linkage of health care 
information between registries, which minimizes loss to follow-up. 
 Databases: WDHR contains information about all cardiac procedures 
performed in Western Denmark since 1999.
11
 The registration is web-based, and contains 
information concerning, patient characteristics, angiographic findings and procedural 
indication and priority. Patients are registered by their personal identifier, which is also used 
in the Danish National Patient Registry (DNPR), that has recorded all hospital-based 
inpatient and outpatient diagnoses since 1977;
12,13
 and the Danish National Database of 
Reimbursed Prescriptions, which contains data on all reimbursed prescriptions at Danish 
pharmacies since 2004.
11,14,15
 
Patient selection: CAG was performed in 97,321 patients. We excluded 
patients aged <18 years (n=33), patients with a diagnosis of AF in DNPR within 30 days after 
the CAG (n=13,226), patients receiving vitamin-K antagonists (n=3,285) or NOACs (n=48) 
according to the Danish National Database of Reimbursed Prescriptions (ATC-codes: 
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B01AA03, B01AA04, B01AF02, B01AE07 and B01AF01),
14,15
 and patients with follow-up 
<30 days(n=1,772). Follow-up started day 30 after CAG. We followed the patients using the 
DNPR to obtain the endpoints ischemic stroke/TIA, systemic embolism, AF, and all-cause 
death.  
 Co-variate definition: Included parameters were the CHA2DS2-VASc score, 
medical treatment with statin (ATC-code: C10AA), antiplatelets (adenosine diphosphate 
(ADP)-receptor inhibitors (ATC-codes: B01AC22, B01AC04, and B01AC24) and aspirin 
(ATC-codes B01AC06 and N02BA01)). Family history of ischemic heart disease (all patients 
were asked about relatives with ischemic heart disease (1 first-generation relative) in 
relation to the CAG procedure), coronary artery disease (CAD) including previous MI, and 
PAD/aortic plaque. All co-variates were registered either 6 months before or 30 days after 
CAG. The parameters were:  
 Congestive heart failure: Defined as congestive heart failure as registered in 
DNPR (ICD-codes: I11.0, I13.0, I13.2, I42.0, I50) or a left ventricular ejection fraction 40% 
obtained from WDHR. 
 Hypertension: Defined as treatment for hypertension according to WDHR or a 
diagnosis of hypertension from DNPR (ICD-codes: I10, I15.1, I15.8, I15.9). 
 Age: Defined as age at index CAG.  
 Diabetes mellitus: Patients were defined as having diabetes mellitus if they 1) 
were registered receiving insulin treatment and/or oral antidiabetic medication or non-
pharmacological dietary treatment as registered in WDHR, 2) redeemed ≥1 prescription for 
antidiabetic medication (ATC-codes: A10A, A10B) in the Danish National Database of 
Reimbursed Prescriptions, or 3) had a diabetes diagnosis in DNPR (ICD-codes: E10-14, 
E36.0, O24.0-24.3, O24.5-24.9). 
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 Stroke/TIA: Defined as a diagnosis of ischemic stroke (ICD-codes I63, I64) or 
TIA (ICD-code G45) registered in DNPR. 
 Vascular disease: Defined as a diagnosis of PAD (ICD-code: I70.1-I70.9, I71, 
I73.9), aortic plaque (ICD-code I70.0), or MI (ICD-code I21) registered in DNPR. 
 Sex category: Defined by WDHR. 
 CHA2DS2-VASc score: Stroke risk factors assigned 1 point were: congestive 
heart failure, hypertension, 65 years  age  75 years, diabetes mellitus, vascular disease, and 
female sex. Stroke risk factors assigned 2 points were stroke/TIA/systemic embolism and age 
75 years.
2,3
 Patients with only 1 point due to female sex were categorised as CHA2DS2-
VASc 0. 
 CAD: Defined as 0 vessel disease (VD), 1 VD, 2 VD, 3 VD or diffuse VD as 
obtained from index CAG and listed in WDHR.  
 Endpoints: The composite of ischemic stroke (ICD-codes: I63, I64), TIA 
(ICD-code: G45) and systemic embolism (ICD-code: I74), ischemic stroke/TIA, systemic 
embolism, AF (ICD-code: I48) and all-cause death. All endpoints were primary or secondary 
hospital discharge diagnoses. AF was defined as an elective diagnosis or a primary or 
secondary hospital discharge diagnosis. All ICD-codes accessed through DNPR.
15
 
Information regarding death obtained through the Civil Registration System.
16
 
 Statistical analysis: Follow-up began 30 days after CAG and continued until 
endpoint event, death, emigration, or end of follow-up, whichever came first. We estimated 
event rates per 100 person-years for the clinical endpoints according to CHA2DS2-VASc 
score. A sensitivity analysis of the composite endpoint was performed, where we censored 
patients developing AF. We plotted the cumulative incidence curves for the levels of the 
CHA2DS2-VASc score for the different clinical endpoints, and furthermore, we performed 
test for trend for all endpoints. Incidence rate ratios (IRR) were estimated for each primary 
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and secondary endpoint using modified Poisson regression. Patients with a low CHA2DS2-
VASc score (0 in males and 1 in females) were used as reference group.
17
 Data were adjusted 
for examination year and antiplatelet treatment (defined as having redeemed a prescription of 
aspirin and/or ADP-inhibitor 6 months before or within 30 days after CAG). Since we are 
using Poisson regression, adjusting for competing risk is not possible. Finally, a multivariate 
analysis of all risk factors in the CHA2DS2-VASc score were performed in order to obtain 
information on each risk factor’s value in the risk prediction. We used Stata/IC software 
version 13.1 (StataCorp, College station, Texas, USA) for all analyses. 
 Ethical considerations: This study complies with the Declaration of Helsinki 
and was approved by the Danish Data Protection Agency (Record no. 2012-41-0914).  
 
RESULTS 
 78,233 patients aged 18 years, without AF and with no previous OAC 
treatment, who underwent CAG between July 1, 2004 and December 31, 2012 were included. 
Among these patients 10,777 (13.8%) were low-risk using the CHA2DS2-VASc score (0 in 
males and 1 in females), 13,024 (16.6%) had CHA2DS2-VASc score 1, 19,882 (25.4%) had 
CHA2DS2-VASc score 2, 15,868 (20.3%) had CHA2DS2-VASc score 3, 10,373 (13.3%) had 
CHA2DS2-VASc score 4 and 8,299 (10.6%) had CHA2DS2-VASc score >4 (Figure 1). 
Maximum follow-up was 8.4 years, and median follow-up was 3.7 years.  
 Baseline characteristics: Baseline characteristics are shown in Table 1. The 
table includes possible risk factors for AF, ischemic stroke and all-cause death. Although 
higher CHA2DS2-VASc scores were associated with increasing extent of CAD, incidence of 
previous MI, and PAD, it is noteworthy that 36% did not have CAD, 65% had no previous 
MI, and only 7% had PAD.  
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 Clinical endpoints: The endpoints are shown in Table 2. The composite 
endpoint ischemic stroke/TIA/systemic embolism occurred incrementally as the CHA2DS2-
VASc score increased (Figure 2, p for trend <0.0001). The rate of ischemic 
stroke/TIA/embolism increased from 0.46 [0.41-0.53] for low-risk patients (CHA2DS2-VASc 
score 0 in males and 1 in females), to 3.45 [3.22-3.69] per 100 person-years for patients with 
CHA2DS2-VASc >4 (p for trend <0.0001). A CHA2DS2-VASc score of 3 corresponded to an 
event rate of 1.30 per 100 person-years. When censoring patients developing AF, the event 
rate slightly decreased to 1.24 per 100 person-years.  
When the IRR were calculated in reference to the low-risk patients (CHA2DS2-
VASc score 0 in males and 1 in females), a CHA2DS2-VASc score >4 corresponded to an 
IRR of 7.41[6.37-8.63] without significant change when adjusting for antiplatelet treatment 
and examination year (Table 2).  
 Similar incremental risks were observed when studying development of AF 
(Figure 2). Patients with low CHA2DS2-VASc scores (0 in male and 1 in female) had an 
event rate of 0.87 [0.79-0.96] while patients with a CHA2DS2-VASc score >4 had an event 
rate of 4.08 [3.84-4.34] per 100 person-years (p for trend <0.0001). The rate of all-cause 
death increased from 0.77 [0.70-0.86] among low-risk patients (CHA2DS2-VASc 0 in males 
and 1 in females) while patients with CHA2DS2-VASc >4 had a rate of all-cause death of 
9.12 [8.77-9.49] per 100 person-years (p for trend <0.0001). Systemic embolism accounted 
only few events.  
Multivariate analysis: In the multivariate analysis of all risk factors in the 
CHA2DS2-VASc score, age 75 years constituted the greatest risk (IRR 2.38 [2.18-2.59]) of 
the composite endpoint. When separating the vascular component into PAD/aortic plaque and 
MI, it revealed the first mentioned having an IRR of 1.52 [1.37-1.69], while previous MI had 
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a non-significant IRR of 1.07 [0.99-1.14]. Female sex had an IRR of 0.87 [0.81-0.93]. IRRs 
for all risk factors are shown in Table 3.    
 
DISCUSSION 
 The main findings in this analysis of 78,233 non-AF patients who had 
undergone CAG were that the CHA2DS2-VASc score predicted a future diagnosis of AF and 
an incremental risk of ischemic stroke/TIA/systemic embolism. A CHA2DS2-VASc score of 
3 was associated with a rate of ischemic events of 1.3 per 100 person-years, which is 
identical to the stroke risk that, according to European guidelines, warrants OAC treatment 
among AF-patients.
2,5
 The current data may therefore provide a background for future stroke 
prevention trials in non-AF patients, including the potential to guide future follow-up for AF 
detection in non-AF patients with high CHA2DS2-VASc scores. 
 
Risk stratification of thromboembolism  
 Only 20-30% of patients suffering thromboembolism are diagnosed with AF 
prior, or in relation, to their ischemic stroke.
10
 In contrast to AF-patients, where the 
CHA2DS2-VASc score is used to guide initiation of prophylactic therapy, there is a 
knowledge gap on how to risk-stratify non-AF patients.  
 The current study showed that the CHA2DS2-VASc score predicted the risk of 
ischemic stroke/TIA/systemic embolism among non-AF patients, which to some extent might 
be due to a higher risk of a future AF diagnosis. The incremental risk of the composite 
thromboembolic endpoint remained significant, however, after censoring patients who 
developed AF. Other studies have already pointed at the possibility that CHADS2 and 
CHA2DS2-VASc can be used in stroke risk stratification among non-AF patients,
18–20
 and an 
association with incident AF has also been reported.
20
 Moreover, higher CHA2DS2-VASc 
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scores have also been associated with an increased risk of AF among post-STEMI patients 
and postoperative patients after cardiac surgery.
21,22
 The largest of the studies evaluating 
CHA2DS2-VASc and the risk of stroke among non-AF patients included 20,970 patients with 
acute coronary syndromes, and the authors reported that both CHADS2 and CHA2DS2-VASc 
were predictors of ischemic stroke/TIA.
20
 Our study was approximately 4 times larger 
(78,233 patients), and included patients with stable CAD. Our study thus extends the 
previous findings to a larger and more generalizable population although still with the caveat 
that even our data are limited to patients with indication for CAG. However, it still suggests 
that the predictive value of the CHA2DS2-VASc score can be applied to much broader 
populations than previously assessed.  
Accessing the weight of the individual risk factors in the CHA2DS2-VASc 
score, when applied on non-AF patients, revealed a strong association between advanced age 
and stroke risk. The second strongest predictor of ischemic stroke was previous ischemic 
stroke/TIA. Furthermore, dividing the vascular component into PAD/aortic plaque and MI, 
revealed that PAD/aortic plaque accounted for a greater risk of stroke than previous MI.  
 
Prevention of ischemic stroke/TIA/systemic embolism in patients without AF 
 Among AF-patients, the tipping point of when stroke risk outweighs risk of 
bleeding, i.e. when anticoagulant treatment is recommended, is an annual risk of 1%.
2,3,23
 
The rate of ischemic stroke/TIA/systemic embolism in patients with a CHA2DS2-VASc score 
of 3 were 1.30 per 100 person-years and the rate was even higher with increasing scores. In 
patients with CHA2DS2-VASc scores 3, it is likely that prophylactic antithrombotic 
treatment may outweigh the risk of bleeding.  
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Recently, secondary cardiovascular prevention among patients with stable 
atherosclerotic vascular disease (CAD and/or PAD) was examined in the COMPASS 
(Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial, where patients 
were randomised to receive rivaroxaban alone, combined with aspirin, or aspirin alone.
24
 The 
primary endpoint was a composite of cardiovascular death, stroke, and MI. The study was 
terminated early due to a difference in the primary efficacy outcome in favour of treatment 
with low-dose rivaroxaban combined with aspirin, but this was at cost of a higher risk of 
major bleeding. In relation to the current study, it is worth noting that the combination 
therapy with rivaroxaban and aspirin did not reduce MI (1.9% vs 2.2%) while the main 
benefit was caused by a 42% relative reduction of ischemic stroke (0.9% vs 1.6%). A non-
significant intermediate reduction of stroke was seen in the rivaroxaban arm alone (1.3%). 
This suggests that combination therapies with platelet inhibitor and low-dose NOAC may 
have the potential to reduce the stroke risk among non-AF patients. In this regard, it is 
important that we, when balancing the benefit of reducing thromboembolism against harm 
from bleeding, can identify patients at high risk of thromboembolism.
25
 Our study may 
provide the missing link by showing that it is possible, in a very large cohort of routine 
clinical care patients, to identify high-risk non-AF patients by use of a well-known clinical 
scoring system. Still, further investigations are needed to define the score where the benefit 
of reducing ischemic stroke and mortality exceeds the risk of major bleeding. 
 
Pathogenesis of thromboembolism in patients without AF 
The pathogenesis of ischemic stroke in non-AF patients may differ from AF-
patients. Ischemic stroke and thromboembolism among AF-patients is thought to be caused 
primarily by embolization of thrombus formed in the left atrial appendage. Still, even in AF-
patients the cause of stroke is not limited to thrombus embolization from the left atrium.
2,19
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Non-AF patients may have, or develop, unrecognized paroxysmal AF as cause 
of ischemic stroke. Indeed, we observed that incremental CHA2DS2-VASc scores was 
significantly associated with a future AF diagnosis, and it seems very likely that 
unrecognized AF play an important role for the higher risk of thromboembolic events 
observed in our cohort study. This association was also found in another study, which 
reported that subclinical episodes of AF occurred frequently in diabetic patients, and that the 
absolute burden of subclinical AF was significantly associated with both size and number of 
silent cerebral infarcts.
26
 Such episodes of subclinical AF was also seen in older patients with 
cardiovascular risk factors,
27
 and AF is often found in cryptogenic stroke patients with 
prolonged monitoring.
28–30
 These observations only make it more important to identify 
patients at high risk of future AF and stroke, and to evaluate strategies for identification and 
risk reduction. Another important cause of ischemic stroke are embolisms from carotid artery 
plaques, which may well be the leading cause of ischemic stroke in non-AF patients. This 
differentiation is not trivial since it remains unknown whether OAC, a superior strategy for 
AF-patients, may be a good prophylactic strategy in non-AF patients.  
 
Limitations 
 This is a registry-based evaluation and our results must primarily be considered 
hypothesis-generating. Moreover, all patients in our study had undergone CAG, which affects 
the external validity, and we can primarily conclude that it is possible to identify a group of 
non-AF patients at high risk of first-time AF, ischemic stroke, and mortality within this CAG 
cohort.  
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Conclusions 
 Among patients without AF, undergoing CAG, the CHA2DS2-VASc score 
predicted a future diagnosis of AF and the composite risk of ischemic stroke, TIA, or 
systemic embolism. A CHA2DS2-VASc score of 3 was associated with a risk that would 
justify prophylactic oral anticoagulation treatment in a patient with atrial fibrillation. 
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FIGURE LEGENDS 
 
Figure 1. Patient flow chart. The flow chart illustrates the inclusion of 78,233 
patients without atrial fibrillation, registered in the Western Denmark Heart Registry, 
and examined by coronary angiography between July 1, 2004 - December 31, 2012. 
 
Figure 2. Cumulated incidence of clinical endpoints in patients without atrial 
fibrillation. Cumulated incidence of A: the composite endpoint ischemic 
stroke/TIA/embolism; B: ischemic stroke/TIA/embolism when censored for development of 
atrial fibrillation; C: ischemic stroke/TIA; D: systemic embolism; E: atrial fibrillation; and F: 
all-cause death. 
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Table 1. Baseline characteristics of 78,233 patients without atrial fibrillation, registered in the Western Denmark Heart Registry, and 
examined by coronary angiography between July 1, 2004 – December 31, 2012. 
 
 CHA2DS2-VASc score 
  
0 (male) or 1 
(female) 
1 (nonfemale) 2 3 4 >4  Total 
  (n = 10,777)) (n = 13,024) (n = 19,882) (n = 15,868) (n = 10,373) (n = 8,299) (n = 78,233) 
  n (%) n (%) n (%) n (%) n (%) n (%) n (%) 
Median follow-up (IQR
*
) (years) 
  4.2 (2.2-6.2) 4.1 (2.1-6.1) 3.9 (1.9-6.0) 3.6 (1.7-5.7) 3.2 (1.5-5.3) 2.8 (1.2-5.0) 3.7 (1.8-5.8) 
CHA2DS2-VASc parameters 
 CHF
†
 0 (0.0) 663 (5.1) 1,926 (9.7) 2,418 (15.2) 2,428 (23.4) 3,440 (41.5) 10,875 (13.9) 
 Hypertension 0 (0.0) 4,997 (38.4) 11,722 (59.0) 11,456 (72.2) 8,441 (81.4) 7,474 (90.1) 44,090 (56.4) 
 Diabetes mellitus 0 (0.0) 418 (3.2) 2,364 (11.9) 3,346 (21.1) 2,718 (26.2) 3,273 (39.4) 12,119 (15.5) 
 Stroke/TIA
‡
 0 (0.0) 0 (0.0) 212 (1.1) 754 (4.8) 1,336 (12.9) 3,540 (42.7) 5,842 (7.5) 
 Vascular disease
§
 0 (0.0) 4,829 (37.1) 7,209 (36.3) 7,022 (44.3) 5,677 (54.7) 6,106 (73.6) 30,843 (39.4) 
Age category 
 <65 years 10,777 (100.0) 10,907 (83.7) 11,952 (60.1) 4,669 (29.4) 1,464 (14.1) 479 (5.8) 40,248 (51.5) 
 65-74 years 0 (0.0) 2,117 (16.3) 7,030 (35.4) 7,731 (48.7) 3,870 (37.3) 2,287 (27.6) 23,035 (29.4) 
 ≥75 years 0 (0.0) 0 (0.0) 900 (4.5) 3,468 (21.9) 5,039 (48.6) 5,533 (66.7) 14,940 (19.1) 
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Gender 
 Male 6,599 (61.2) 13,024 (100.0) 12,593 (63.3) 8,681 (54.7) 4,765 (45.9) 3,231 (38.9) 48,893 (62.5) 
 Female 4,178 (38.8) 0 (0.0) 7,289 (36.7) 7,187 (45.3) 5,608 (54.1) 5,068 (61.1) 29,330 (37.5) 
Other characteristics 
 Family history
||
 5,060(47.0) 5,636 (43.3) 8,731 (43.9) 6,129 (38.6) 3,634 (35.0) 2,660 (32.1) 31,850 (40.7) 
 Previous MI
#
 0 (0.0) 4,670 (35.9) 6,592 (33.2) 6,172 (38.9) 4,733 (45.6) 5,074 (61.1) 27,241 (34.8) 
 PAD
**
/aortic plaque 0 (0.0) 256 (2.0) 886 (4.5) 1,287 (8.1) 1,455 (14.0) 1,882 (22.7) 5,766 (7.4) 
Vessel disease 
 0 VD
††
 7,354 (68.2) 4,196 (32.2) 7,432 (37.4) 4,878 (30.7) 2,602 (25.1) 1,367 (16.5) 27,829 (35.6) 
 1 VD 1,686 (15.6) 4,397 (33.8) 5,558 (28.0) 4,356 (27.5) 2,790 (26.9) 2,056 (24.8) 20,843 (26.6) 
 2 VD 642 (6.0) 2,068 (15.9) 2,978 (15.0) 2,730 (17.2) 1,884 (18.2) 1,742 (21.0) 12,044 (15.4) 
 3 VD 446 (4.1) 1,474 (11.3) 2,453 (12.3) 2,654 (16.7) 2,247 (21.7) 2,483 (29.9) 11,757 (15.0) 
 Diffuse VD 649 (6.0) 889 (6.8) 1,461 (7.3) 1,250 (7.9) 850 (8.2) 651 (7.8) 5,750 (7.4) 
Smoking 
 Active 3,353 (31.1) 4,879 (37.5) 6,256 (31.5) 4,167 (26.3) 2,339 (22.5) 1,606 (19.4) 22,600 (28.9) 
 Never 3,428 (31.8) 2,967 (22.8) 5,216 (26.2) 4,389 (27.7) 2,970 (28.6) 2,363 (28.5) 21,333 (27.3) 
 Former 2,998 (27.8) 3,996 (30.7) 6,656 (33.5) 5,796 (36.5) 4,053 (39.1) 3,351 (40.4) 26.850 (34.3) 
Medication 
 Statin 5,211 (48.4) 9,783 (75.1) 14,948 (75.2) 12,702 (48.4) 8,332 (48.4) 6,884 (48.4) 57,860 (48.4) 
 DAPT
‡‡
 844 (7.8) 3,226 (24.8) 4,717 (23.7) 4,238 (26.7) 3,047 (29.4) 3,003 (36.2) 19,075 (24.4) 
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 Any antiplatelets
§§
 5,386 (50.0) 9,783 (75.1) 15,353 (77.2) 13,409 (84.5) 9,074 (87.5) 7,611 (91.7) 60,616 (77.5) 
 Aspirin 5,089 (47.2) 8,972 (68.9) 14,490 (72.9) 12,842 (80.9) 8,669 (83.6) 7,199 (86.7) 57.261 (73.2) 
 ADP
||||
-inhibitors 1,141 (10.6) 4,037 (31.0) 5,580 (28.1) 4,805 (30.3) 3,452 (33.3) 3,415 (41.1) 22,430 (28.7) 
 
 
*
 IQR: Interquartile range 
†
 CHF: Congestive heart failure 
‡ 
TIA: Transient ischemic attack 
§
 Vascular disease: Defined as previous myocardial infarction and/or PAD/aortic plaque 
||
 Family history of ischemic heart disease (at least one 1
st
 generation relative). Patients were asked in relation to CAG-procedure. 
# 
MI: Myocardial infarction 
**
 PAD: Peripheral artery disease 
 
†† 
VD: Vessel disease 
 
‡‡ 
DAPT: Dual antiplatelet treatment with Aspirin and ADP-inhibitor 6 months before or 30 days after coronary angiography 
 
§§ 
Antiplatelet treatment with Aspirin and/or ADP-inhibitor 6 months before or 30 days after coronary angiography 
 
|||| 
ADP: Adenosine diphosphate receptor 
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Table 2. Clinical endpoints for 78,233 coronary angiography patients with no history of atrial 
fibrillation. Patients were grouped according to their CHA2DS2-VASc score. The endpoints 
were ischemic stroke/TIA
*
/systemic embolism, ischemic stroke/TIA/embolism when censured for 
development of atrial fibrillation, ischemic stroke/TIA, systemic embolism, atrial fibrillation, and 
all-cause death.  
      Ischemic stroke/TIA/systemic embolism 
CHA2DS2-VASc 
score Patients Events 
Rate per 100 
person-years 
Unadjusted IRR
†
  
(95% CI
‡
) 
Adjusted
§
 IRR  
(95% CI) 
0 (male) or 1 
(female) 10,777 208 0.46 [0.41-0.53] 1 [reference] 1 [reference] 
1 (nonfemale) 13,024 359 0.68 [0.62-0.76] 1.47 [1.24-1.74] 1.50 [1.27-1.79] 
2  19,882 663 0.86 [0.80-0.93] 1.85 [1.58-2.16] 1.89 [1.62-2.21] 
3  15,868 752 1.30 [1.21-1.40] 2.80 [2.40-3.26] 2.88 [2.46-3.37] 
4  10,373 680 1.97 [1.83-2.13] 4.24 [3.63-4.95] 4.37 [3.72-5.12] 
>4 8,299 852 3.45 [3.22-3.69] 7.41 [6.37-8.63] 7.65 [6.54-8.96] 
      Ischemic stroke/TIA/systemic embolism. Censored for development of atrial fibrillation 
0 (male) or 1 
(female) 10,777 200 0.46 [0.40-0.53] 1 [reference] 1 [reference] 
1 (nonfemale) 13,024 328 0.65 [0.58-0.72] 1.41 [1.19-1.69] 1.46 [1.22-1.74] 
2  19,882 609 0.82 [0.76-0.89] 1.80 [1.53-2.11] 1.85 [1.57-2.17] 
3  15,868 678 1.24 [1.15-1.33] 2.70 [2.31-3.16] 2.80 [2.38-3.29] 
4  10,373 614 1.90 [1.75-2.05] 4.15 [3.36-4.86] 4.30 [3.65-5.07] 
>4  8,299 783 3.40 [3.17-3.65] 7.43 [6.36-8.68] 7.74 [6.58-9.10] 
      Ischemic stroke/TIA 
0 (male) or 1 
(female) 10,777 199 0.44 [0.39-0.51] 1 [reference] 1 [reference] 
1 (nonfemale) 13,024 343 0.65 [0.59-0.73] 1.47 [1.23-1.75] 1.50 [1.26-1.79] 
2  19,882 637 0.82 [0.76-0.89] 1.85 [1.58-2.17] 1.90 [1.62-2.23] 
3  15,868 725 1.25 [1.16-1.35] 2.82 [2.41-3.30] 2.91 [2.48-3.41] 
4  10,373 647 1.87 [1.73-2.02] 4.21 [3.59-4.94] 4.35 [3.69-5.11] 
>4  8,299 829 3.35 [3.13-3.58] 7.53 [6.45-8.80] 7.79 [6.64-9.15] 
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      Systemic embolism 
0 (male) or 1 
(female) 10,777 9 0.02 [0.01-0.04] 1 [reference] 1 [reference] 
1 (nonfemale) 13,024 18 0.03 [0.02-0.05] 1.70 [0.76-3.78] 1.63 [0.74-3.61] 
2  19,882 32 0.04 [0.03-0.06] 2.05 [0.98-4.28] 1.95 [0.94-4.04] 
3  15,868 32 0.05 [0.04-0.08] 2.70 [1.29-5.67] 2.54 [1.22-5.31] 
4  10,373 38 0.11 [0.08-0.15] 5.32 [2.57-10.99] 4.98 [2.44-10.16] 
>4  8,299 27 0.10 [0.07-0.15] 5.14 [2.42-10.94] 4.80 [2.29-10.08] 
      Atrial fibrillation 
0 (male) or 1 
(female) 10,777 385 0.87 [0.79-0.96] 1 [reference] 1 [reference] 
1 (nonfemale) 13,024 715 1.39 [1.29-1.50] 1.60 [1.41-1.81] 1.72 [1.51-1.95] 
2  19,882 1,216 1.61 [1.53-1.71] 1.85 [1.65-2.08] 1.99 [1.77-2.24] 
3  15,868 1,352 2.40 [2.28-2.53] 2.75 [2.46-3.09] 3.02 [2.69-3.39] 
4  10,373 1,095 3.26 [3.07-3.46] 3.74 [3.33-4.21] 4.11 [3.65-4.64] 
>4  8,299 997 4.08 [3.84-4.34] 4.68 [4.16-5.27] 5.19 [4.59-5.86] 
            
All-cause death 
0 (male) or 1 
(female) 10,777 350 0.77 [0.70-0.86] 1 [reference] 1 [reference] 
1 (nonfemale) 13,024 677 1.27 [1.18-1.37] 1.64 [1.44-1.87] 1.73 [1.52-1.97] 
2  19,882 1,464 1.86 [1.77-1.96] 2.40 [2.14-2.70] 2.56 [2.28-2.88] 
3  15,868 2,015 3.38 [3.24-3.54] 4.38 [3.91-4.90] 4.74 [4.22-5.31] 
4  10,373 1,972 5.48 [5.24-5.72] 7.08 [6.32-7.93] 7.72 [6.88-8.67] 
>4 8,299 2,412 9.12 [8.77-9.49] 11.80 [10.55-13.20] 12.99 [11.59-14.56] 
      
*
 TIA: Transient ischemic attack  
†
 IRR: incidence rate ratio  
‡
 CI: Confidence interval 
§
 Adjusted for examination year and antiplatelet therapy 6 months before or 30 days after coronary 
angiography 
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Table 3. Multivariate adjusted Poisson regression including components in the 
CHA2DS2-VASc score, estimating the relative risk of ischemic stroke, TIA
*
, and 
systemic embolism in a non-AF
†
 cohort. The vascular component is both included as a 
combined variable and divided into PAD
‡
/aortic plaque and myocardial infarction. IRRs
§
 are 
calculated in reference to patients without the condition, IRRs in the age categories are 
calculated in reference to patients <65 years.  
 
Risk factor Adjusted
||
 IRR [95%CI
#
] 
Female sex 0.87 [0.81-0.93] 
Age 65-74 years 1.54 [1.42-1.67] 
Age ≥75 years 2.38 [2.18-2.59] 
Congestive heart failure 1.30 [1.19-1.42] 
Hypertension 1.25 [1.16-1.34] 
Diabetes mellitus 1.45 [1.33-1.57] 
Stroke/TIA 1.93 [1.85-2.01] 
Vascular disease 1.18 [1.10-1.26] 
 Myocardial infarction
**
 1.07 [0.99-1.14] 
 PAD/aortic plaque
**
 1.52 [1.37-1.69] 
 
*
 TIA: Transient ischemic attack 
†
 AF: Atrial fibrillation 
‡
 PAD: Peripheral artery disease 
§
 IRR: Incidence rate ratio 
||
 Adjusted for all other risk factors included in the CHA2DS2-VASc score 
#
 CI: Confidence interval 
**
 Multivariate Poisson regression where the vascular component is divided into PAD/aortic 
plaque and myocardial infarction where both are considered as individual risk factors. 
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